WDNA vs. CNCR

Last updated Jun 5, 2026

WDNA (WisdomTree BioRevolution Fund) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds - WDNA tracks the WisdomTree BioRevolution Index while CNCR tracks the Loncar Cancer Immunotherapy Index. Both are passively managed. WDNA charges 0.45%/yr vs 0.79%/yr for CNCR.

Performance

WDNA vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in WisdomTree BioRevolution Fund (WDNA) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

WDNA

• 1D: 2.94%
• 1M: 2.56%
• YTD: 8.96%
• 6M: 10.44%
• 1Y: 50.50%
• 3Y*: 3.54%
• 5Y*: -4.78%
• 10Y*: —

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

WDNA vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
WDNA WisdomTree BioRevolution Fund	2.90%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

WDNA vs. CNCR - Sectors Allocation Comparison

Sectors	WDNA	CNCR
Healthcare	85.0%	96.6%
Basic Materials	6.5%	-
Consumer Defensive	3.0%	-
Energy	1.1%	-
Communication Services	-	-
Consumer Cyclical	-	-
Financial Services	-	3.3%
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

WDNA vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

WDNA

WDNA Risk / Return Rank: 63
WDNA Sharpe Ratio Rank: 59
WDNA Sortino Ratio Rank: 62
WDNA Omega Ratio Rank: 53
WDNA Calmar Ratio Rank: 83
WDNA Martin Ratio Rank: 57

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

WDNA vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for WisdomTree BioRevolution Fund (WDNA) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	WDNA	CNCR	Difference
Sharpe ratio: Return per unit of total volatility	1.98	—	—
Sortino ratio: Return per unit of downside risk	2.85	—	—
Omega ratio: Gain probability vs. loss probability	1.32	—	—
Calmar ratio: Return relative to maximum drawdown	4.34	—	—
Martin ratio: Return relative to average drawdown	9.85	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	WDNA	CNCR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.98	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.19	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.19	—	—

Drawdowns

WDNA vs. CNCR - Drawdown Comparison

The maximum WDNA drawdown since its inception was -58.87%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for WDNA and CNCR.

Drawdown Indicators

	WDNA	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-58.87%	0.00%	-58.87%
Max Drawdown (1Y) Largest decline over 1 year	-11.70%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-38.25%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-58.87%	—	—
Current Drawdown Current decline from peak	-29.86%	0.00%	-29.86%
Average Drawdown Average peak-to-trough decline	-35.64%	0.00%	-35.64%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.14%	—	—

Volatility

Volatility by Period

	WDNA	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.35%	—	—
Volatility (6M) Calculated over the trailing 6-month period	16.59%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	25.66%	0.00%	+25.66%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	25.08%	0.00%	+25.08%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	25.07%	0.00%	+25.07%

WDNA vs. CNCR - Expense Ratio Comparison

WDNA has a 0.45% expense ratio, which is lower than CNCR's 0.79% expense ratio.

Dividends

WDNA vs. CNCR - Dividend Comparison

WDNA's dividend yield for the trailing twelve months is around 4.19%, while CNCR has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
WDNA WisdomTree BioRevolution Fund	4.19%	4.57%	0.75%	0.80%	0.38%	0.10%

Frequently Asked Questions

Which ETF is better, WDNA or CNCR?

On fees, WDNA is cheaper at 0.45% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, WDNA or CNCR?

WDNA is cheaper with a 0.45% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, WDNA or CNCR?

WDNA has the higher dividend yield at 4.19%, compared with 0.00% for CNCR.

What is the main difference between WDNA and CNCR?

WDNA tracks WisdomTree BioRevolution Index, while CNCR tracks Loncar Cancer Immunotherapy Index. They also come from different issuers: WisdomTree and Exchange Traded Concepts. Their fees differ too: 0.45% for WDNA and 0.79% for CNCR.